Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

MRSA/SA test, 7/13:104

Cepheid has received FDA clearance to market its Xpert MRSA/SA blood culture test, which runs on its GeneXpert system, for the detection of methicillin-resistant Staphylococcus aureus and S. aureus in blood culture bottles showing gram-positive cocci in clusters in about one hour. Cepheid’s updated Xpert MRSA/SA BC test processes positive blood culture specimens to determine whether a patient’s blood is infected with MRSA or SA, which are frequent causes of sepsis in hospitalized patients. “Having the capability to differentiate MRSA, S.

CAP 15189 renewal for National Jewish Health, 7/13:104

The College of American Pathologists has renewed CAP 15189 Accreditation for National Jewish Health Advanced Diagnostic Laboratories. The accreditation, based on standard 15189 for laboratory technical competence and continual quality management, is administered by the International Organization for Standardization and seeks to improve patient safety and reduce risk, by outlining standards for quality and competence in medical laboratories. CAP 15189 is a voluntary, non-regulatory accreditation to the ISO 15189:2007 standard as published by ISO. The program complements CAP accreditation and

Remote microscopy telepathology tool, 7/13:104

MikroScan Technologies’ Live-Q telepathology tool works as an add-on to the company’s D2 desktop whole slide scanner, which enhances remote viewing and remote control of the device. Keith J. Kaplan, MD, surgical pathologist and producer of the Digital Pathology Blog, recently tested the Live-Q user experience in a café over a standard typical Wi-Fi connection. He wrote in his review, “In summary, this system works on every level. It’s fast, it’s responsive, it’s intuitive, it’s high quality, and it’s easy

Troponin I assay, 7/13:104

Beckman Coulter has received FDA 510(k) clearance for its Access AccuTnI+3 troponin I assay for use on its Access 2 immunoassay system. In accordance with FDA requirements, the company conducted a large multicenter prospective clinical trial on the AccuTnI+3 troponin I assay that enrolled more than 1,900 subjects, and confirmed that the assay provides the clinical performance necessary for optimal patient management. The data from this trial show that Beckman Coulter’s Access AccuTnI+3 troponin I assay provides the precision, clinical

Rabbit monoclonal antibodies portfolio, 7/13:104

Bio SB offers a portfolio of more than 130 rabbit monoclonal antibodies. “Rabbit monoclonal antibodies offer higher sensitivity and specificity when compared to mouse monoclonal antibodies traditionally used in laboratory applications,” Alfonso Heras, president and CEO of Bio SB, said in a statement. “Coupled with our new line of detection systems and chromogens, such as our PolyDetector HRP Plus, PolyDetector AP, and HRP Green, Bio SB can offer a large array of immunohistochemistry products to pathologists around the world.”

Hematology analyzer, 6/13:96

Beckman Coulter’s UniCel DxH 600 Coulter cellular analysis system is a benchtop hematology analyzer for mid- to high-volume laboratories. The system provides laboratories with exceptional quality results, improved first-pass accuracy, and automatic rerun and reflex testing, thereby reducing overall manual review rates and processes.

Next-generation lab automation solution

Abbott has launched its Accelerator a3600 next-generation automation solution, which helps laboratories process tests faster while handling increased volume. The Accelerator a3600 processes up to 3,600 samples per hour and handles multiple tube sizes and types simultaneously.

Multiplexing system with GI pathogen panel, 6/13:96

Luminex has received FDA clearance for its Magpix instrument with the xTAG gastrointestinal pathogen panel (xTAG GPP). This is the first clinical assay to be cleared on Magpix. xTAG GPP simultaneously detects 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample.

Fecal occult blood test, 6/13:96

Sekisui Diagnostics’ OSOM rapid immunochemical fecal occult blood test detects hemoglobin in stool samples as an aid in the early detection of colorectal cancer. The OSOM test provides sample stability: a unique “dry-sample” collection card; value: two patient sample collections on one collection card allow compliance with screening guidelines, using only one test cassette; and a comprehensive physician and patient support Web site.

MARKETPLACE

TRENDING